Antiphospholipid Antibodies Affect Human Endometrial Angiogenesis: Protective Effect of a Synthetic Peptide (TIFI) Mimicking the Phospholipid Binding Site of β2glycoprotein I. (7th May 2013)

• Record Type: Journal Article
• Authors: Di Simone, Nicoletta; D'Ippolito, Silvia; Marana, Riccardo; Di Nicuolo, Fiorella; Castellani, Roberta; Pierangeli, Silvia S.; Chen, Pojen; Tersigni, Chiara; Scambia, Giovanni; Meroni, Pier Luigi
• Is Part Of: American journal of reproductive immunology. Volume 70:Number 4(2013:Oct.)
• Page Start: 299
• Page End: 308
• Publication Date: 2013-05-07
• Subjects: Human reproduction -- Immunological aspects -- Periodicals; 616.69206
• DOI: 10.1111/aji.12130
• Languages: English
• ISSNs: 1046-7408

Abstract

<abstract abstract-type="main" xml:lang="en" id="aji12130-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="aji12130-sec-0001" sec-type="section"> <title>Problem</title> <p>Aim of our study was to investigate whether TIFI, a syntetic peptide able to compete with anti‐phospholipid antibodies (aPL) in the binding to endothelium, may restore aPL‐inhibited endometrial angiogenesis.</p> </sec> <sec id="aji12130-sec-0002" sec-type="section"> <title>Methods</title> <p>The protective role of TIFI was evaluated on: i) aPL–inhibited of human endometrial endothelial cells (HEEC) angiogenesis <italic>in vitro</italic>; ii) aPL–inhibited vascular endothelial growth factor (VEGF) and metalloproteases (MMPs) expression; iii) aPL‐inhibited Nuclear Factor‐κB (NF‐κB) and Extracellular signal–Regulated Kinase (ERK) activation and (iv) angiogenesis <italic>in vivo</italic>.</p> </sec> <sec id="aji12130-sec-0003" sec-type="section"> <title>Results</title> <p>TIFI restores in a dose‐dependent manner: i) aPL‐mediated inhibition of HEEC angiogenesis <italic>in vitro</italic> and <italic>in vivo</italic> (<italic>P</italic> < 0.05), ii) VEGF (<italic>P</italic> < 0.001) and MMP–2 (<italic>P</italic> < 0.05) expression and iii) NF‐κB DNA binding and ERK–1/2 activation (<italic>P</italic> < 0.05) inhibited by aPL.</p> </sec> <sec id="aji12130-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Our results show for the first time the protective effects of TIFI, as represented by its ability to interfere with aPL mediated anti‐angiogenic activity.</p> </sec> </abstract>